Europe Viral Vector Manufacturing Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Europe Viral Vector Manufacturing Market size is expected to reach US$ 2,063.2 Million by 2031 from US$ 615.8 Million in 2024. The market is estimated to record a CAGR of 19.1% from 2025 to 2031.

Executive Summary and Europe Viral Vector Manufacturing Market Analysis:

The viral vector manufacturing in Europe landscape is characterized by a strong emphasis on innovation, regulatory rigor, and collaborative networks across multiple countries. The region benefits from a mature pharmaceutical industry, with countries such as Germany, the UK, France, and Switzerland emerging as centers of excellence for gene therapy research and viral vector production. Countries such as Germany, the United Kingdom, and France are at the forefront of viral vector manufacturing, with a growing number of Good Manufacturing Practice (GMP)-certified facilities and contract manufacturing organizations (CMOs). European manufacturers often focus on integrating advanced manufacturing techniques with stringent quality standards required by the European Medicines Agency (EMA), ensuring product safety and efficacy. The region's collaborative framework, supported by initiatives from the European Union, fosters cross-border partnerships between academia, biotech companies, and manufacturing entities, accelerating the development and commercialization of viral vectors. The European Union's Horizon Europe program, with an allocation of EUR 11.5 billion (US$ 12.6 billion) to support progress in biotechnology and pharmaceutical research and development, and Invest EU's contribution of over EUR 1 billion (US$ 1.1 billion) toward biotech and medicine-focused projects, are expected to drive innovation and growth in viral vector production across Europe. In 2025, companies such as Bavarian Nordic are considering ramping up production of their mpox vaccine, exploring technology transfer to enable local vaccine production in Africa, which could reduce vaccine costs while maintaining quality.

Europe Viral Vector Manufacturing Market: Strategic Insights

Europe Viral Vector Manufacturing Market Segmentation Analysis:

• By Type, the Europe Viral Vector Manufacturing Market is segmented into Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, and Others. The Adenoviral Vectors segment dominated the market in 2024.
• By Disease Indication, the Europe Viral Vector Manufacturing Market is segmented into Cancer, Genetic Disorders, Infectious Diseases, and Others. The Cancer segment dominated the market in 2024.
• By Application, the Europe Viral Vector Manufacturing Market is segmented into Therapeutics Development, Vaccine Development, and Research. The Therapeutics Development segment dominated the market in 2024.
• By End User, the Europe Viral Vector Manufacturing Market is segmented into Pharmaceutical and Biotechnology Companies, CDMOs and CROs, and Research Institutes. The Pharmaceutical and Biotechnology Companies segment dominated the market in 2024.

Europe Viral Vector Manufacturing Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Viral Vector Manufacturing Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Europe Viral Vector Manufacturing Market Outlook

The surge in clinical development is increasing the demand for viral vectors and fueling significant investments, infrastructure development, and technological advancements across both public and private manufacturing sectors. Gene and cell therapies are entering clinical trials, with a particular focus on targeting rare genetic disorders, hematologic malignancies, and neurological diseases. These therapies rely heavily on viral vectors such as adeno-associated virus (AAV), lentivirus, and adenovirus for gene delivery. As more programs advance into later phases, where vector requirements increase in both volume and quality, manufacturers face mounting pressure to expand their production capacities. Reflecting this trend, several important developments have occurred between 2023 and 2025. In Europe, Novartis opened its first dedicated viral vector production plant in Mengeš, Slovenia, in 2025. Named VIFA One, this fully automated facility supports cell and gene therapies for cancer and genetic diseases. This plant is part of a broader 3.5 billion (~US$3.8 billion) investment into biomanufacturing infrastructure in Slovenia. Biomanufacturing companies have also responded to growing demand. In 2023, SK Pharmteco's subsidiary Yposkesi doubled its GMP viral vector production capacity with a major expansion in France. These developments highlight a clear connection: as clinical pipelines expand, viral vector manufacturers must simultaneously scale production. The growing complexity and regulatory demands of late-stage clinical programs necessitate enhanced quality control, automation, and adherence to Good Manufacturing Practices. This direct link between clinical demand and manufacturing readiness remains a key driver of market growth.

Europe Viral Vector Manufacturing Market Country Insights

By country, the Europe Viral Vector Manufacturing Market is segmented into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. Germany held the largest share in 2024.

Germany is one of the major hubs for viral vector manufacturing in Europe. Its strong life sciences base, advanced biomanufacturing infrastructure, and established pharmaceutical companies make it a leader in scaling up production of viral vectors (especially AAV, lentivirus, etc.). Germany benefits from both private and public investment in cell & gene therapy research and development, and a skilled workforce in biotech, engineering, and regulatory affairs. Regulatory clarity under EU frameworks and Germany's ability to meet GMP and quality standards also support growth. Additionally, collaborations between academic institutions, startups, CDMOs, and large pharma drive innovation and enable process technological improvements (e.g., in upstream/downstream manufacturing, purification). In September 2024, Rentschler Biopharma announced a new lentiviral vector manufacturing "toolbox" for advanced therapies, expanding its services at its German site and also at its UK facility in Steven age. This reflects a trend among German-based CDMOs to strengthen their viral vector capabilities. Meanwhile, Germany continues to benefit from its strong biotech ecosystem (e.g., BioNTech as a major biotech in Germany). Germany's market is growing steadily, driven by strong funding, regulatory support, and demand for advanced therapies, but tempered by rising costs, regulatory burdens, and capacity constraints.
 

Europe Viral Vector Manufacturing Market Company Profiles

Some of the key players operating in the market include Charles River Laboratories International Inc, Novartis AG, Catalent Inc, Lonza Group AG, Merck KGaA, GenScript Biotech Corporation, Takara Bio Inc, FUJIFILM Holdings Corp, WuXi AppTec Co Ltd, and Thermo Fisher Scientific Inc.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Viral Vector Manufacturing Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise